Upsher Smith Labs Company Profile
✉ Email this page to a colleague
What is the competitive landscape for UPSHER SMITH LABS, and what generic alternatives to UPSHER SMITH LABS drugs are available?
UPSHER SMITH LABS has eighty-nine approved drugs.
There are eight US patents protecting UPSHER SMITH LABS drugs.
There are seventeen patent family members on UPSHER SMITH LABS drugs in ten countries and one hundred and thirty-four supplementary protection certificates in thirteen countries.
Summary for Upsher Smith Labs
| International Patents: | 17 |
| US Patents: | 8 |
| Tradenames: | 69 |
| Ingredients: | 63 |
| NDAs: | 89 |
Drugs and US Patents for Upsher Smith Labs
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Upsher Smith Labs | MORPHINE SULFATE | morphine sulfate | CAPSULE, EXTENDED RELEASE;ORAL | 202104-005 | Jun 3, 2013 | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Upsher Smith Labs | OXYBUTYNIN CHLORIDE | oxybutynin chloride | TABLET;ORAL | 074625-001 | Jul 31, 1996 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Upsher Smith Labs | QUDEXY XR | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 205122-004 | Mar 11, 2014 | AB2 | RX | Yes | No | 8,889,190 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
| Upsher Smith Labs | BETHANECHOL CHLORIDE | bethanechol chloride | TABLET;ORAL | 040636-001 | Jun 1, 2005 | AA | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Upsher Smith Labs | BEXAROTENE | bexarotene | CAPSULE;ORAL | 209886-001 | Jul 25, 2018 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Upsher Smith Labs | QUDEXY XR | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 205122-004 | Mar 11, 2014 | AB2 | RX | Yes | No | 9,555,005 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
| Upsher Smith Labs | CLOBAZAM | clobazam | SUSPENSION;ORAL | 210569-001 | Oct 22, 2018 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Upsher Smith Labs
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Upsher Smith Labs | FORTICAL | calcitonin salmon recombinant | SPRAY, METERED;NASAL | 021406-001 | Aug 12, 2005 | RE43580 | ⤷ Try a Trial |
| Upsher Smith Labs | FORTICAL | calcitonin salmon recombinant | SPRAY, METERED;NASAL | 021406-001 | Aug 12, 2005 | 6,440,392 | ⤷ Try a Trial |
| Upsher Smith Labs | FORTICAL | calcitonin salmon recombinant | SPRAY, METERED;NASAL | 021406-001 | Aug 12, 2005 | RE40812 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for UPSHER SMITH LABS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Nasal Spray | 200 IU/spray | ➤ Subscribe | 2006-03-29 |
| ➤ Subscribe | Extended-release Capsules | 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg | ➤ Subscribe | 2015-12-24 |
International Patents for Upsher Smith Labs Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 101674509 | ⤷ Try a Trial |
| South Africa | 201604587 | ⤷ Try a Trial |
| Israel | 241053 | ⤷ Try a Trial |
| South Korea | 20160124930 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2014143380 | ⤷ Try a Trial |
| European Patent Office | 2968177 | ⤷ Try a Trial |
| Hong Kong | 1223852 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Upsher Smith Labs Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0113964 | 97C0037 | Belgium | ⤷ Try a Trial | PRODUCT NAME: OESTROGENES EQUINS CONJUGUES; ACETATE DE MEDROXYPROGESTERONE; NAT. REGISTRATION NO/DATE: NL 19569 19950301; FIRST REGISTRATION: CH - 52647 01 010 19940826 |
| 1441735 | 08C0026 | France | ⤷ Try a Trial | PRODUCT NAME: RALTEGRAVIR POTASSIUM; REGISTRATION NO/DATE: EU/1/07/436/001 20080102 |
| 1874117 | SPC/GB14/041 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING DOLUTEGRAVIR SODIUM; REGISTERED: UK EU/1/13/892/001-006 20140121 |
| 1912999 | 14C0076 | France | ⤷ Try a Trial | PRODUCT NAME: SIMEPREVIR OU L'UN DE SES SELS, INCLUANT LE SEL DE SODIUM DE SIMEPREVIR; REGISTRATION NO/DATE: EU/1/14/924 20140516 |
| 1912999 | 1490062-5 | Sweden | ⤷ Try a Trial | PRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516 |
| 1499331 | SPC/GB13/034 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313 |
| 2822954 | 18C1035 | France | ⤷ Try a Trial | PRODUCT NAME: BICTEGRAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER BICTEGRAVIR DE SODIUM; REGISTRATION NO/DATE: EU/1/18/1289 20180625 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
